Upturn unsubscribed user
$1.14/ day, billed weekly
Cancel anytime
(Ad-Free, Unlimited access)​
NO CREDIT CARD REQUIRED
STAA logo STAA
Upturn stock ratingUpturn stock rating
STAA logo

STAAR Surgical Company (STAA)

Upturn stock ratingUpturn stock rating
$16.78
Last Close (24-hour delay)
upturn advisory
PASS
  • BUY Advisory
  • SELL Advisory (Profit)​
  • SELL Advisory (Loss)​
  • Profit
  • Loss
  • Pass (Skip investing)
Upturn Stock infoUpturn Stock info Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • YEAR
  • MONTH
  • WEEK

Upturn Advisory Summary

06/30/2025: STAA (1-star) is currently NOT-A-BUY. Pass it for now.

Upturn Star Rating

rating

Not Recommended Performance

These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.

Number of Analysts

rating

14 Analysts rated it

Well-followed company, solid analyst reports, reliable data for confident investing.

1 Year Target Price $19.1

1 Year Target Price $19.1

Analysts Price Target For last 52 week
$19.1Target price
Low$13.5
Current$16.78
high$49.86

Analysis of Past Performance

Type Stock
Historic Profit -7.16%
Avg. Invested days 28
Today’s Advisory PASS
Upturn Star Rating Upturn stock ratingUpturn stock rating
Upturn Advisory Performance Upturn Advisory Performance 2.0
Stock Returns Performance Upturn Returns Performance 1.0
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Upturn Profits based on simulationUpturn Profits based on simulation Last Close 06/30/2025

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 837.98M USD
Price to earnings Ratio -
1Y Target Price 19.1
Price to earnings Ratio -
1Y Target Price 19.1
Volume (30-day avg) 14
Beta 0.61
52 Weeks Range 13.50 - 49.86
Updated Date 06/30/2025
52 Weeks Range 13.50 - 49.86
Updated Date 06/30/2025
Dividends yield (FY) -
Basic EPS (TTM) -1.44

Analyzing Revenue: Products, Geography and Growth

Revenue by Products

Product revenue - Year on Year

Revenue by Geography

Geography revenue - Year on Year

Earnings Date

Report Date -
When -
Estimate -
Actual -

Profitability

Profit Margin -25.46%
Operating Margin (TTM) -81.43%

Management Effectiveness

Return on Assets (TTM) -5.9%
Return on Equity (TTM) -19.14%

Valuation

Trailing PE -
Forward PE 625
Enterprise Value 651403841
Price to Sales(TTM) 3
Enterprise Value 651403841
Price to Sales(TTM) 3
Enterprise Value to Revenue 2.33
Enterprise Value to EBITDA 42.84
Shares Outstanding 49526100
Shares Floating 30182860
Shares Outstanding 49526100
Shares Floating 30182860
Percent Insiders 0.64
Percent Institutions 109.46

Analyst Ratings

Rating 4
Target Price 19.1
Buy -
Strong Buy 3
Buy -
Strong Buy 3
Hold 10
Sell -
Strong Sell 1
Strong Sell 1

ai summary icon Upturn AI SWOT

STAAR Surgical Company

stock logo

Company Overview

overview logo History and Background

STAAR Surgical Company was founded in 1982. It focuses on the design, development, manufacture, and marketing of implantable lenses for the eye. A significant milestone includes FDA approval for its Visian ICL (Implantable Collamer Lens). The company has evolved from offering a broader range of ophthalmic products to focusing on refractive lenses.

business area logo Core Business Areas

  • Implantable Lenses: This segment involves the manufacturing and sale of implantable lenses (ICLs) for the correction of myopia (nearsightedness), hyperopia (farsightedness), and astigmatism. This is STAAR's primary revenue driver.
  • Other Ophthalmic Products: This smaller segment includes other surgical products, such as phacoemulsification products used in cataract surgery.

leadership logo Leadership and Structure

STAAR Surgical Company is led by Tom Frinzi (President and CEO). The organizational structure includes departments for Research and Development, Manufacturing, Sales and Marketing, Finance, and Operations.

Top Products and Market Share

overview logo Key Offerings

  • Visian ICL: The Visian ICL is STAAR Surgical's flagship product, an implantable collamer lens used for correcting myopia, hyperopia, and astigmatism. Market share estimates vary but STAAR is estimated to hold 20% of the market. Revenue is centered around this product, but exact data is not publicly available. Competitors include Johnson & Johnson Vision, Alcon, and Carl Zeiss Meditec.
  • Toric ICL: The Toric ICL is a variation of the Visian ICL designed to correct astigmatism along with myopia or hyperopia. Market share is likely included within the overall ICL market share. Competitors are the same as for Visian ICL

Market Dynamics

industry overview logo Industry Overview

The ophthalmic surgical market is driven by an aging population, increasing prevalence of refractive errors, and technological advancements. It is competitive with key players focusing on innovation in surgical procedures and devices.

Positioning

STAAR Surgical Company holds a strong position in the refractive lens market, particularly with its ICL technology. Its competitive advantages include its proprietary Collamer material and its minimally invasive surgical procedure.

Total Addressable Market (TAM)

The global refractive surgery market is expected to reach approximately $6.0 billion to $7.0 billion, with STAAR Surgical Company targeting a significant portion of this market through its ICL products. They are positioned to continue growing within this market.

Upturn SWOT Analysis

Strengths

  • Proprietary Collamer Material
  • Minimally Invasive Surgical Procedure
  • Strong Brand Recognition (Visian ICL)
  • Focus on Refractive Lenses
  • Growing Global Presence

Weaknesses

  • Reliance on a Single Product Category (ICL)
  • Smaller Market Share Compared to Larger Competitors
  • Geographic Concentration of Sales
  • Manufacturing Capacity Limitations

Opportunities

  • Expanding into New Geographies
  • Developing New ICL Models (e.g., for Presbyopia)
  • Increasing Awareness of ICL Technology
  • Strategic Partnerships with Ophthalmic Surgeons
  • Capturing a larger portion of the TAM through increased market awareness

Threats

  • Competition from Laser Vision Correction (LASIK, SMILE)
  • Technological Advancements by Competitors
  • Economic Downturns Affecting Elective Procedures
  • Regulatory Changes in Key Markets
  • Supply Chain Disruptions

Competitors and Market Share

competitor logo Key Competitors

  • ALC
  • JNJ
  • CAJZY

Competitive Landscape

STAAR Surgical Company faces competition from larger, more diversified ophthalmic companies. Its competitive advantages include its proprietary Collamer material and its focus on ICL technology. However, it needs to address its reliance on a single product category and manufacturing capacity limitations.

Growth Trajectory and Initiatives

Historical Growth: STAAR Surgical has experienced significant growth in recent years, driven by increasing ICL sales and expanding global presence.

Future Projections: Analyst estimates project continued revenue growth for STAAR Surgical, supported by increasing demand for ICL products and geographic expansion. However, growth rates are expected to moderate as the company scales.

Recent Initiatives: Recent strategic initiatives include expanding sales and marketing efforts in key markets, investing in R&D for new ICL models, and optimizing manufacturing capacity.

Summary

STAAR Surgical is a growing company with strong revenue increases centered on its ICL product line. Its proprietary technology and minimally invasive procedure give them a competitive edge. They should be wary of competitors innovating in laser vision correction and capacity limits on manufacturing. STAAR Surgical is positioned for continued growth as long as they meet the demand.

Peer Comparison

Sources and Disclaimers

Data Sources:

  • Company Filings (SEC)
  • Analyst Reports
  • Industry Publications
  • Company Website

Disclaimers:

This analysis is based on publicly available information and analyst estimates. It is not financial advice. Investment decisions should be made after consulting with a qualified financial advisor. Market share figures are estimates and may vary. Forward looking statements cannot be gauranteed.

Upturn AI SummarizationUpturn AI Summarization AI Summarization is directionally correct and might not be accurate.

Upturn AI SummarizationUpturn AI Summarization Summarized information shown could be a few years old and not current.

Upturn AI SummarizationUpturn AI Summarization Fundamental Rating based on AI could be based on old data.

Upturn AI SummarizationUpturn AI Summarization AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.

About STAAR Surgical Company

Exchange NASDAQ
Headquaters Lake Forest, CA, United States
IPO Launch date 1983-07-15
CEO & Director Mr. Stephen C. Farrell CFA
Sector Healthcare
Industry Medical Instruments & Supplies
Full time employees 1157
Full time employees 1157

STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, and sells implantable lenses for the eye and accessory delivery systems to deliver the lenses into the eye. The company provides implantable Collamer lens product family (ICLs) and laser-based procedures, such as LASIK to treat visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia. It serves its products to health care providers, including ophthalmic surgeons, vision and surgical centers, hospitals, government facilities, and distributors, as well as products are primarily used by ophthalmologists. The company sells its products directly through its sales representatives in the United States, Japan, Germany, Spain, Canada, the United Kingdom, and Singapore, as well as through representatives and independent distributors in China, Korea, India, France, Benelux, Italy, and internationally. STAAR Surgical Company was incorporated in 1982 and is headquartered in Lake Forest, California.